Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Mehta, J. Curwin, J. Gomes, V. Fuster (1997)
Sudden death in coronary artery disease: acute ischemia versus myocardial substrate.Circulation, 96 9
S. Pogwizd, R. Hoyt, J. Saffitz, P. Corr, J. Cox, M. Cain (1992)
Reentrant and Focal Mechanisms Underlying Ventricular Tachycardia in the Human HeartCirculation, 86
J. McMurray, J. Kjekshus, L. Gullestad, P. Dunselman, Å. Hjalmarson, H. Wedel, M. Lindberg, F. Waagstein, P. Grande, J. Hradec, G. Kamenský, J. Korewicki, T. Kuusi, F. Mach, N. Ranjith, J. Wikstrand (2009)
Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective AnalysisCirculation, 120
Yuval Konstantino, J. Kusniec, T. Reshef, Ofer David-Zadeh, A. Mazur, B. Strasberg,, A. Battler, M. Haim (2007)
Inflammatory Biomarkers are not Predictive of Intermediate‐term Risk of Ventricular Tachyarrhythmias in Stable CHF PatientsClinical Cardiology, 30
D. Owens, G. Sanders, P. Heidenreich, K. McDonald, M. Hlatky (2002)
Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.American heart journal, 144 3
G. Liuzzo, L. Biasucci, J. Gallimore, R. Grillo, A. Rebuzzi, M. Pepys, A. Maseri (1994)
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.The New England journal of medicine, 331 7
A. Buxton, Kerry Lee, J. Fisher, M. Josephson, E. Prystowsky, G. Hafley (1999)
A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.The New England journal of medicine, 341 25
H. Blangy, N. Sadoul, B. Dousset, A. Radauceanu, R. Fay, E. Aliot, F. Zannad (2007)
Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 9 9
J. Goldberger (2009)
Evidence-based analysis of risk factors for sudden cardiac death.Heart rhythm, 6 3 Suppl
C. Linde, W. Abraham, M. Gold, M. Sutton, S. Ghio, C. Daubert (2008)
Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.Journal of the American College of Cardiology, 52 23
P. Scott, J. Barry, P. Roberts, J. Morgan (2009)
Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta‐analysisEuropean Journal of Heart Failure, 11
A. Moss, W. Hall, D. Cannom, H. Klein, Mary Brown, J. Daubert, N. Estes, E. Foster, H. Greenberg, S. Higgins, M. Pfeffer, S. Solomon, D. Wilber, W. Zareba (2009)
Cardiac-resynchronization therapy for the prevention of heart-failure events.The New England journal of medicine, 361 14
M. Bristow, L. Saxon, J. Boehmer, S. Krueger, D. Kass, T. Marco, P. Carson, L. DiCarlo, D. DeMets, B. White, Dale Devries, A. Feldman (2004)
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.The New England journal of medicine, 350 21
L. Biasucci, G. Giubilato, G. Biondi-Zoccai, T. Sanna, G. Liuzzo, M. Piro, G. Martino, C. Ierardi, Alessio Russo, G. Pelargonio, F. Bellocci, F. Crea (2006)
C reactive protein is associated with malignant ventricular arrhythmias in patients with ischaemia with implantable cardioverter-defibrillatorHeart, 92
J. Ix, M. Shlipak, G. Chertow, M. Whooley (2006)
Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease: Data From the Heart and Soul StudyCirculation, 115
L. Biasucci (2004)
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice Clinical Use of Inflammatory Markers in Patients With Cardiovascular Diseases A Background PaperCirculation, 110
G. Blake, N. Rifai, J. Buring, P. Ridker (2003)
Blood Pressure, C-Reactive Protein, and Risk of Future Cardiovascular EventsCirculation: Journal of the American Heart Association, 108
F. Beer, C. Hind, K. Fox, R. Allan, A. Maseri, M. Pepys (1982)
Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction.British Heart Journal, 47
D. Morrow, E. Braunwald (2003)
Future of Biomarkers in Acute Coronary Syndromes Moving Toward a Multimarker StrategyCirculation, 108
(2004)
What causes sudden death in heart failure?
C. Currie, C. Poole, P. Conway (2007)
Evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortalityHeart, 94
R. Pedretti, A. Curnis, R. Massa, F. Morandi, M. Tritto, L. Manca, E. Occhetta, G. Molon, G. Ferrari, S. Braga, G. Raciti, C. Klersy, J. Salerno-Uriarte (2010)
Proportion of patients needing an implantable cardioverter defibrillator on the basis of current guidelines: impact on healthcare resources in Italy and the USA. Data from the ALPHA study registry.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 12 8
A. Buxton (2005)
Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator.Circulation, 111 19
A. Moss, W. Hall, D. Cannom, J. Daubert, Steven Higgins, Helmut Klein, Joseph Levine, Sanjeev Saksena, Albert Waldo, David Wilber, Mary Brown, Moonseong Heo (1996)
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.The New England journal of medicine, 335 26
C. Albert, Jing Ma, N. Rifai, M. Stampfer, P. Ridker (2002)
Prospective Study of C-Reactive Protein, Homocysteine, and Plasma Lipid Levels as Predictors of Sudden Cardiac DeathCirculation: Journal of the American Heart Association, 105
A. Buxton (2005)
Not Everyone With an Ejection Fraction ≤30% Should Receive an ICDCirculation, 111
C. Bickel, H. Rupprecht, S. Blankenberg, Christine Espiniola-Klein, A. Schlitt, G. Rippin, G. Hafner, Rainer Treude, H. Othman, Klaus-Peter Hofmann, Jürgen Meyer (2002)
Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease.The American journal of cardiology, 89 8
Ori Galante, G. Amit, D. Zahger, A. Wagshal, R. Ilia, A. Katz (2008)
B‐type Natruiretic Peptide Levels Stratify the Risk for Arrhythmia Among Implantable Cardioverter Defibrillator PatientsClinical Cardiology, 31
G. Bardy, Kerry Lee, D. Mark, J. Poole, D. Packer, R. Boineau, M. Domanski, C. Troutman, Jill Anderson, G. Johnson, S. McNulty, N. Clapp-Channing, L. Davidson-Ray, Elizabeth Fraulo, D. Fishbein, R. Luceri, J. Ip (2005)
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.The New England journal of medicine, 352 3
I. Goldenberg, J. Gillespie, A. Moss, W. Hall, H. Klein, S. McNitt, Mary Brown, I. Cygankiewicz, W. Zareba (2010)
Long-Term Benefit of Primary Prevention With an Implantable Cardioverter-Defibrillator: An Extended 8-Year Follow-Up Study of the Multicenter Automatic Defibrillator Implantation Trial IICirculation, 122
STEVEN Greenberg, Andrew Epstein, T. Deering, D. Goldman, M. Ghidina, Curtis Neason, A. Proclemer (2007)
A Comparison of ICD Implantations in the United States Versus ItalyPacing and Clinical Electrophysiology, 30
J. Oss, W. Areba, W. Ackson, H. Lein, D. Ilber, D. Annom, J. Ames, P. Aubert, S. Iggins, M. Rown, M. Ndrews (2002)
PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTIONThe New England Journal of Medicine, 346
Hong Yu, H. Oswald, A. Gardiwal, C. Lissel, G. Klein (2007)
Comparison of N-terminal pro-brain natriuretic peptide versus electrophysiologic study for predicting future outcomes in patients with an implantable cardioverter defibrillator after myocardial infarction.The American journal of cardiology, 100 4
A. Verma, F. Kılıçaslan, D. Martin, S. Minor, R. Starling, N. Marrouche, S. Almahammed, O. Wazni, S. Duggal, R. Zuzek, H. Yamaji, J. Cummings, M. Chung, P. Tchou, A. Natale (2005)
Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapiesHeart, 92
DavendraMehta, JayCurwin, J. AnthonyGomes, ValentinFuster (1997)
Sudden Death in Coronary Artery DiseaseCirculation
N. Every, A. Hallstrom, K. McDonald, L. Parsons, D. Thom, D. Weaver, M. Hlatky (2002)
Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease.American heart journal, 144 3
G. Novo, G. Amoroso, G. Fazio, F. Sutera, S. Novo (2009)
Biomarkers in heart failure.Frontiers in bioscience, 14
M. Panteghini, F. Apple, R. Christenson, F. Dati, J. Mair, A. Wu (1999)
Proposals from IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD): recommendations on use of biochemical markers of cardiac damage in acute coronary syndromes.Scandinavian journal of clinical and laboratory investigation. Supplementum, 230
R. Schwartz, A. Burke, A. Farb, D. Kaye, J. Lesser, T. Henry, R. Virmani (2009)
Microemboli and microvascular obstruction in acute coronary thrombosis and sudden coronary death: relation to epicardial plaque histopathology.Journal of the American College of Cardiology, 54 23
P. Toth (2010)
Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective AnalysisYearbook of Endocrinology, 2010
G. Kozdağ, G. Ertas, T. Kilic, E. Acar, A. Ağır, T. Şahin, M. Çetin, Ulaş Bildirici, D. Ural (2010)
Elevated level of high-sensitivity C-reactive protein is important in determining prognosis in chronic heart failure.Medical science monitor : international medical journal of experimental and clinical research, 16 3
Rajet Deo, M. Shlipak, J. Ix, Sadia Ali, N. Schiller, M. Whooley (2009)
Association of Cystatin C with Ischemia in Patients with Coronary Heart DiseaseClinical Cardiology, 32
A. Burke, R. Tracy, F. Kolodgie, G. Malcom, A. Zieske, R. Kutys, J. Pestaner, J. Smialek, R. Virmani (2002)
Elevated C-Reactive Protein Values and Atherosclerosis in Sudden Coronary Death: Association With Different PathologiesCirculation: Journal of the American Heart Association, 105
A. Kadish, A. Dyer, J. Daubert, R. Quigg, N. Estes, Kelley Anderson, H. Calkins, D. Hoch, J. Goldberger, A. Shalaby, William Sanders, A. Schaechter, Joseph Levine (2004)
Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.The New England journal of medicine, 350 21
K. Filion, Xuanqian Xie, Charlotte Avoort, N. Dendukuri, J. Brophy (2009)
Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: A cost-effectiveness studyInternational Journal of Technology Assessment in Health Care, 25
Tomohiko Ai, Y. Fujiwara, K. Tsuji, H. Otani, Shozo Nakano, Y. Kubo, M. Horie (2002)
Novel KCNJ2 Mutation in Familial Periodic Paralysis With Ventricular DysrhythmiaCirculation: Journal of the American Heart Association, 105
D. Zipes, A. Camm, M. Borggrefe, A. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, George Klein, A. Moss, R. Myerburg, S. Priori, M. Quiñones, D. Roden, M. Silka, C. Tracy (2006)
Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.Revista Espanola De Cardiologia, 59
J. Bigger (1986)
Relation between left ventricular dysfunction and ventricular arrhythmias after myocardial infarction.The American journal of cardiology, 57 3
F. Streitner, J. Kuschyk, C. Veltmann, Desiree Ratay, N. Schoene, Ines Streitner, M. Brueckmann, B. Schumacher, M. Borggrefe, C. Wolpert (2009)
Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm.Cytokine, 47 3
I. Anand, R. Latini, V. Florea, M. Kuskowski, T. Rector, S. Masson, S. Signorini, P. Mocarelli, A. Hester, R. Glazer, J. Cohn (2005)
C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of ValsartanCirculation, 112
A. Proclemer, M. Ghidina, Gloria Cicuttini, D. Gregori, P. Fioretti (2006)
Impact of the Main Implantable Cardioverter‐Defibrillator Trials for Primary and Secondary Prevention in Italy: A Survey of the National Activity During the Years 2001–2004Pacing and Clinical Electrophysiology, 29
P. Ridker, M. Cushman, M. Stampfer, R. Tracy, C. Hennekens (1997)
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.The New England journal of medicine, 336 14
J. Bailey, A. Berson, H. Handelsman, M. Hodges (2001)
Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction.Journal of the American College of Cardiology, 38 7
F. Bellocci, L. Biasucci, G. Gensini, L. Padeletti, A. Raviele, M. Santini, G. Giubilato, M. Landolina, G. Biondi-Zoccai, G. Raciti, M. Sassara, A. Castro, A. Kheir, F. Crea (2007)
Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) studyJournal of Cardiovascular Medicine, 8
AimsPatients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can be offered therapy with implantable cardioverter defibrillators (ICDs). Whether plasma biomarkers can help risk stratify for SCD and ventricular arrhythmias (VT/VF) is unclear.Methods and resultsThe primary objective of the CAMI-GUIDE study is to assess the predictive role of C-reactive protein for SCD or VT/VF in ischaemic patients with the ejection fraction <30% and ICDs. Secondary endpoints included all-cause mortality, hospitalizations, and death from heart failure. Additional analyses incorporated cystatin-C and NT-ProBNP in multi-marker approach for the prediction of adverse outcomes. A total of 300 patients were enrolled. All-cause mortality at 2 years was 22.6%, mortality from heart failure was 8.3%. Primary endpoint occurred in 17.3%. At a competing risk multivariable analysis adjusted for baseline variables, no significant difference in primary endpoint was found between patients with C-reactive protein ≤3 vs. >3 mg/L [heart rate (HR) 0.91 (0.50–1.64) P = 0.76], while C-reactive protein >3 mg/L was strongly associated with mortality due to heart failure [HR: 3.17 (1.54–6.54) P = 0.002]. NT-proBNP above median was significantly associated with the primary endpoint [adjusted HR: 1.46 (1.020–2.129) P = 0.042]. A risk function, including the three biomarkers, NYHA class and resting HR, allowed stratification of patient mortality risk from 5 to 50%.ConclusionC-reactive protein >3 mg/L is not associated with SCD or fast VT/VF, however, is a strong predictor of HF mortality. Biomarkers combined with clinical markers allow an excellent risk stratification of mortality at 2 years.
European Heart Journal – Oxford University Press
Published: Jun 26, 2012
Keywords: Sudden cardiac death Myocardial infarction Implantable cardioverter defibrillator C-reactive protein Brain natriuretic peptide
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.